Sequent Scientific [SEQUENT] vs RPG Life Sciences [RPGLIFE] Detailed Stock Comparison

Sequent Scientific

NSE
Loading...

RPG Life Sciences

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sequent Scientific wins in 6 metrics, RPG Life Sciences wins in 13 metrics, with 0 ties. RPG Life Sciences appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricSequent ScientificRPG Life SciencesBetter
P/E Ratio (TTM)158.4621.51RPG Life Sciences
Price-to-Book Ratio6.527.41Sequent Scientific
Debt-to-Equity Ratio62.470.00RPG Life Sciences
PEG Ratio1.33-12.43RPG Life Sciences
EV/EBITDA30.5723.23RPG Life Sciences
Profit Margin (TTM)1.85%27.82%RPG Life Sciences
Operating Margin (TTM)7.56%17.95%RPG Life Sciences
EBITDA Margin (TTM)7.56%17.95%RPG Life Sciences
Return on Equity2.84%34.54%RPG Life Sciences
Return on Assets (TTM)1.37%27.86%RPG Life Sciences
Free Cash Flow (TTM)$442.73M$418.30MSequent Scientific
Dividend YieldN/A1.50%N/A
1-Year Return4.20%4.19%Sequent Scientific
Price-to-Sales Ratio (TTM)2.875.99Sequent Scientific
Enterprise Value$50.77B$36.68BSequent Scientific
EV/Revenue Ratio3.175.58Sequent Scientific
Gross Profit Margin (TTM)46.86%64.47%RPG Life Sciences
Revenue per Share (TTM)$64$397RPG Life Sciences
Earnings per Share (Diluted)$1.16$110.57RPG Life Sciences
Beta (Stock Volatility)0.91-0.37RPG Life Sciences
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Sequent Scientific vs RPG Life Sciences Stock Performance Analysis

Loading Price Chart...

Sequent Scientific
RPG Life Sciences
Sequent Scientific Stock Overview | RPG Life Sciences Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sequent Scientific1.03%8.60%10.16%-2.21%27.87%0.25%
RPG Life Sciences0.96%1.42%1.38%10.13%14.46%8.04%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sequent Scientific4.20%67.80%22.76%25.94%25.94%25.94%
RPG Life Sciences4.19%221.58%485.73%1,434.99%2,332.70%1,612.81%

News Based Sentiment: Sequent Scientific vs RPG Life Sciences

Sequent Scientific

News based Sentiment: POSITIVE

The month of September was exceptionally positive for Sequent Scientific, highlighted by shareholder approval of a transformative merger and remarkably strong financial results. These developments signal a clear upward trajectory for the company and reinforce its growth potential, making it a significant month for investors.

View Sequent Scientific News Sentiment Analysis

RPG Life Sciences

News based Sentiment: MIXED

RPG Life Sciences reported mixed Q1 FY25-26 results with income up but profitability down, creating a mixed investment picture. However, the company continues to benefit from the RPG Group's ambitious growth plans and positive market reaction to its strong FY2025 performance, making it a noteworthy story for investors.

View RPG Life Sciences News Sentiment Analysis

Performance & Financial Health Analysis: Sequent Scientific vs RPG Life Sciences

MetricSEQUENTRPGLIFE
Market Information
Market Cap i₹45.94B₹39.33B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i347,3657,620
90 Day Avg. Volume i486,20816,736
Last Close₹187.59₹2,396.00
52 Week Range₹117.35 - ₹240.70₹1,835.00 - ₹2,974.95
% from 52W High-22.06%-19.46%
All-Time High₹336.50 (Jun 28, 2021)₹2,974.95 (Oct 14, 2024)
% from All-Time High-44.25%-19.46%
Growth Metrics
Quarterly Revenue Growth0.13%0.02%
Quarterly Earnings Growth1.20%-0.02%
Financial Health
Profit Margin (TTM) i0.02%0.28%
Operating Margin (TTM) i0.08%0.18%
Return on Equity (TTM) i0.03%0.35%
Debt to Equity (MRQ) i62.470.00
Cash & Liquidity
Book Value per Share (MRQ)₹28.19₹320.78
Cash per Share (MRQ)₹2.52₹159.99
Operating Cash Flow (TTM) i₹360.47M₹1.08B
Levered Free Cash Flow (TTM) i₹218.78M₹1.83B
Dividends
Last 12-Month Dividend Yield iN/A1.50%
Last 12-Month Dividend i₹0.00₹36.00

Valuation & Enterprise Metrics Analysis: Sequent Scientific vs RPG Life Sciences

MetricSEQUENTRPGLIFE
Price Ratios
P/E Ratio (TTM) i158.4621.51
Forward P/E i36.4083.20
PEG Ratio i1.33-12.43
Price to Sales (TTM) i2.875.99
Price to Book (MRQ) i6.527.41
Market Capitalization
Market Capitalization i₹45.94B₹39.33B
Enterprise Value i₹50.77B₹36.68B
Enterprise Value Metrics
Enterprise to Revenue i3.175.58
Enterprise to EBITDA i30.5723.23
Risk & Other Metrics
Beta i0.91-0.37
Book Value per Share (MRQ) i₹28.19₹320.78

Financial Statements Comparison: Sequent Scientific vs RPG Life Sciences

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)SEQUENTRPGLIFE
Revenue/Sales i₹4.41B₹1.69B
Cost of Goods Sold i₹2.35B₹600.20M
Gross Profit i₹2.07B₹1.09B
Research & Development iN/AN/A
Operating Income (EBIT) i₹333.50M₹303.30M
EBITDA i₹505.30M₹407.00M
Pre-Tax Income i₹255.20M₹354.30M
Income Tax i₹79.50M₹91.40M
Net Income (Profit) i₹175.70M₹262.90M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)SEQUENTRPGLIFE
Cash & Equivalents i₹626.60M₹287.00M
Total Current Assets i₹8.74B₹4.65B
Total Current Liabilities i₹5.05B₹1.20B
Long-Term Debt i₹3.00BN/A
Total Shareholders Equity i₹7.70B₹5.31B
Retained Earnings i₹1.25B₹4.74B
Property, Plant & Equipment i₹2.84B₹1.61B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)SEQUENTRPGLIFE
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSEQUENTRPGLIFE
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i347,3657,620
Average Daily Volume (90 Day) i486,20816,736
Shares Outstanding i249.89M16.54M
Float Shares i117.77M4.29M
% Held by Insiders i0.53%0.71%
% Held by Institutions i0.13%0.09%

Dividend Analysis & Yield Comparison: Sequent Scientific vs RPG Life Sciences

MetricSEQUENTRPGLIFE
Last 12-Month Dividend i₹0.00₹36.00
Last 12-Month Dividend Yield iN/A1.50%
3-Year Avg Annual Dividend i₹0.00₹19.20
3-Year Avg Dividend Yield iN/A1.17%
3-Year Total Dividends i₹0.00₹57.60
Ex-Dividend DateN/AJun 27, 2025